Mediclinic International plc (ANHGY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mediclinic International plc (ANHGY) trades at $5.49 with AI Score 44/100 (Grade C). Mediclinic International plc operates a network of private hospitals across multiple countries, offering a range of healthcare services. Market cap: $4.05B, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for ANHGY: ANHGY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ANHGY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ANHGY: the 1 perspectives are evenly split.
Mediclinic International plc (ANHGY) Healthcare & Pipeline Overview
Mediclinic International plc is a leading provider of private healthcare services, operating 74 hospitals and numerous outpatient facilities across Switzerland, South Africa, Namibia, the Middle East, and the UK, distinguished by its multidisciplinary approach and strong brand presence.
What Is the Investment Thesis for ANHGY?
Mediclinic International plc presents a compelling investment thesis based on its established market presence and diversified service offerings. The company's market capitalization stands at $4.05 billion, with a price-to-earnings ratio of 26.01, indicating robust investor interest. Mediclinic's ongoing expansion of its healthcare facilities and services positions it to capitalize on the growing demand for private healthcare in its operating regions. With a profit margin of 4.7% and a gross margin of 15.6%, the company demonstrates effective cost management and operational efficiency. Key growth catalysts include the increasing prevalence of chronic diseases and an aging population, which are driving demand for specialized healthcare services. Additionally, Mediclinic's strategic investments in technology and patient care innovations are expected to enhance service delivery and patient satisfaction, further solidifying its competitive advantage in the healthcare sector. However, potential risks include regulatory challenges and economic fluctuations that could impact patient volumes and revenue growth.
Based on FMP financials and quantitative analysis
ANHGY Key Highlights
- Market capitalization of $4.05 billion reflects strong investor confidence in the healthcare sector.
- P/E ratio of 26.01 indicates a premium valuation relative to peers, highlighting growth expectations.
- Profit margin of 4.7% and gross margin of 15.6% showcase operational efficiency in healthcare delivery.
- Diverse service offerings across 74 hospitals and various outpatient facilities enhance market reach.
- Stable employee base of 33,683 supports extensive operational capabilities and service delivery.
Who Are ANHGY's Competitors?
ANHGY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| CAKFY McKesson Europe AG | $4.10 | +0.00% | $5.37B | 35 |
| DCHPF Dechra Pharmaceuticals PLC | $46.90 | -0.21% | $5.34B | 48 |
| GALNF Galenica AG | $115.00 | +0.00% | $5.73B | 46 |
| HWAIF Healwell AI Inc. | $0.59 | -1.09% | $174.61M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
| SLHGP Skylight Health Group Inc. | $12.00 | -5.88% | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ANHGY's Key Strengths?
- Extensive network of healthcare facilities across multiple regions.
- Strong brand reputation for quality and specialized care.
- Diverse service offerings catering to various patient needs.
- Operational efficiencies resulting in favorable profit margins.
What Are ANHGY's Weaknesses?
- Limited presence in certain high-growth emerging markets.
- Dependence on regulatory approvals and healthcare policies.
- Potential challenges in managing operational costs and staffing.
- No dividend yield may deter income-focused investors.
What Could Drive ANHGY Stock Higher?
- Expansion of healthcare facilities in emerging markets to capture growing demand.
- Implementation of technological advancements in patient care and management.
- Strategic partnerships with pharmaceutical companies to enhance service offerings.
- Potential regulatory changes that may favor private healthcare providers.
- Continuous improvement in operational efficiencies to enhance profit margins.
What Are the Key Risks for ANHGY?
- Regulatory changes impacting operational frameworks and compliance.
- Economic fluctuations affecting patient volumes and revenues.
- Intense competition from other healthcare providers in key markets.
- Currency risk associated with international operations and ADR trading.
- Challenges related to staffing and operational costs in healthcare facilities.
What Are the Growth Opportunities for ANHGY?
- Growth opportunity 1: The increasing incidence of chronic diseases globally is anticipated to drive demand for specialized healthcare services. The global chronic disease management market is projected to reach $7 trillion by 2027, presenting a significant opportunity for Mediclinic to expand its service offerings and patient base in this growing segment.
- Growth opportunity 2: The aging population in key markets, particularly in Europe and North America, is expected to increase the demand for healthcare services. By 2030, the number of people aged 65 and older is projected to reach 1.5 billion worldwide, creating a substantial opportunity for Mediclinic to enhance its geriatric care services and facilities.
- Growth opportunity 3: Technological advancements in healthcare, such as telemedicine and digital health solutions, are transforming patient care delivery. Mediclinic can leverage these technologies to improve patient engagement and operational efficiency, potentially capturing a larger share of the growing digital health market, which is expected to exceed $640 billion by 2026.
- Growth opportunity 4: Expansion into emerging markets presents a significant growth avenue for Mediclinic. With increasing healthcare access and investment in healthcare infrastructure in regions such as Africa and the Middle East, Mediclinic can establish new facilities and partnerships to tap into these high-growth markets.
- Growth opportunity 5: Strategic partnerships and collaborations with pharmaceutical and biotechnology companies can enhance Mediclinic's service offerings. By integrating innovative therapies and treatments into its healthcare services, Mediclinic can attract a broader patient demographic and improve patient outcomes.
What Opportunities Does ANHGY Have?
- Growing demand for private healthcare services due to chronic diseases.
- Expansion into emerging markets with increasing healthcare access.
- Technological advancements improving patient care delivery.
- Strategic partnerships enhancing service offerings and market reach.
What Threats Does ANHGY Face?
- Intense competition from other healthcare providers.
- Regulatory changes impacting operational frameworks.
- Economic fluctuations affecting patient volumes and revenues.
- Potential risks associated with healthcare reimbursements and insurance.
What Are ANHGY's Competitive Advantages?
- Strong brand recognition in the healthcare sector enhances patient trust.
- Diverse service offerings provide a comprehensive healthcare solution.
- Established network of facilities across multiple countries increases accessibility.
- Commitment to quality care and patient satisfaction fosters loyalty.
- Operational efficiencies and economies of scale reduce costs and improve margins.
What Does ANHGY Do?
Founded in 1983 and headquartered in Stellenbosch, South Africa, Mediclinic International plc has established itself as a prominent player in the private healthcare sector. The company operates under the Mediclinic and Hirslanden brand names, offering a comprehensive range of specialist-oriented and multidisciplinary healthcare services. With a network of 74 hospitals, 20 day case clinics, 22 outpatient clinics, 5 subacute hospitals, and 2 mental health facilities, Mediclinic provides approximately 11,538 inpatient beds across various regions, including Switzerland, South Africa, Namibia, the Middle East, and the United Kingdom. The company’s operations extend beyond healthcare delivery; it also offers services such as treasury management, hospital equipment procurement, emergency medical services, and healthcare management. Mediclinic's commitment to high-quality patient care is reflected in its extensive facilities, which include 453 theatres and a robust management of healthcare staff. The company’s strategic focus on innovation and quality has positioned it well within the competitive landscape of private healthcare, enabling it to meet the diverse needs of its patients and adapt to the evolving healthcare environment.
What Products and Services Does ANHGY Offer?
- Operate a network of private hospitals and healthcare facilities.
- Provide specialist-oriented and multidisciplinary healthcare services.
- Manage outpatient clinics and day case clinics for various medical needs.
- Offer emergency medical services and healthcare management solutions.
- Engage in hospital equipment procurement and related services.
- Provide mental health services and subacute care facilities.
How Does ANHGY Make Money?
- Generate revenue through patient services in private hospitals and clinics.
- Offer specialized healthcare services to cater to diverse patient needs.
- Engage in procurement and management services for healthcare facilities.
- Provide ancillary services such as food and catering, and debt collection.
- Leverage property management and intellectual property holdings for additional revenue.
What Industry Does ANHGY Operate In?
The healthcare industry, particularly the private medical care facilities segment, is experiencing significant growth driven by an increasing demand for specialized healthcare services. The global healthcare market is projected to grow at a CAGR of approximately 7.9% from 2021 to 2028, fueled by factors such as an aging population, rising chronic disease prevalence, and advancements in medical technology. Within this competitive landscape, Mediclinic International plc stands out due to its extensive network of facilities and a strong brand reputation. Competitors such as ARHCF, ASPHF, CAKFY, DCHPF, and GALNF are also vying for market share, but Mediclinic's diverse service offerings and commitment to quality care provide a significant competitive edge.
Who Are ANHGY's Key Customers?
- Patients seeking private healthcare services in various regions.
- Insurance companies providing coverage for healthcare services.
- Government and public health organizations requiring private healthcare partnerships.
- Corporate clients seeking employee health services and wellness programs.
- Healthcare professionals and specialists collaborating with Mediclinic.
ANHGY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, potentially signaling confidence in Mediclinic's future prospects.
- The community seems optimistic about Mediclinic's expansion into new markets, viewing it as a growth driver.
- Positive sentiment revolves around Mediclinic's strong brand reputation, seen as a competitive advantage in the healthcare sector.
- The general perception is that Mediclinic is well-positioned to benefit from the aging global population and increasing demand for healthcare services.
Bear Case
- Some community members express concern about increased regulatory scrutiny in the healthcare industry, potentially impacting Mediclinic's operations.
- There's a bearish view that Mediclinic's debt levels could become a burden if interest rates continue to rise, limiting financial flexibility.
- Negative sentiment focuses on potential challenges integrating recent acquisitions, which could strain resources and management attention.
- Market perception suggests Mediclinic faces stiff competition from other major healthcare providers, potentially limiting market share gains.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ANHGY Latest News
No recent news available for ANHGY.
ANHGY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANHGY.
Price Targets
Wall Street price target analysis for ANHGY.
ANHGY MoonshotScore
What does this score mean?
The MoonshotScore rates ANHGY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Carel Aron van der Merwe D.A. M.B.Ch.B.
CEO
Carel Aron van der Merwe holds a medical degree and has extensive experience in healthcare management. He has held various leadership roles within Mediclinic and has a strong background in clinical practice and healthcare administration, contributing to the company’s strategic direction and operational success.
Track Record: Under Carel's leadership, Mediclinic has expanded its network of facilities and enhanced its service offerings, positioning the company for sustained growth in the competitive healthcare landscape.
Mediclinic International plc ADR Information Unsponsored
An American Depositary Receipt (ADR) is a negotiable certificate issued by a U.S. bank representing shares in a foreign company's stock. ANHGY is classified as a Level 1 ADR, allowing U.S. investors to trade shares of Mediclinic International plc on the OTC market, providing easier access to international investments.
- Home Market Ticker: Stellenbosch, ZA
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ANHG
ANHGY OTC Market Information
The OTC Other tier includes stocks that do not meet the stringent listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have lower liquidity and less stringent reporting requirements, making them accessible to a broader range of investors but potentially riskier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity compared to major exchange-listed stocks may lead to higher volatility.
- Less stringent reporting requirements can result in less transparency.
- Potential for wider bid-ask spreads impacting trading costs.
- Regulatory risks associated with OTC market trading.
- Verify the availability of recent financial statements.
- Assess the company's competitive position within the healthcare sector.
- Investigate the management team's experience and track record.
- Review any recent news or developments affecting the company.
- Evaluate the potential impact of regulatory changes on operations.
- Established brand presence in the healthcare sector.
- Compliance with local regulations and healthcare standards.
- Transparent communication of financial performance and strategies.
- Recognition from industry awards and certifications.
What Investors Ask About Mediclinic International plc (ANHGY) — Healthcare
What does Mediclinic International plc do?
Mediclinic International plc operates a network of private hospitals and healthcare facilities, offering specialized and multidisciplinary healthcare services. The company manages a variety of healthcare services, including outpatient clinics, emergency medical services, and mental health facilities, across multiple countries.
What do analysts say about ANHGY stock?
Analysts view ANHGY as a significant player in the healthcare sector, noting its strong market presence and diversified service offerings. Key valuation metrics indicate a premium P/E ratio compared to peers, reflecting growth expectations. Analysts emphasize the company's operational efficiencies and potential for expansion in emerging markets.
What are the main risks for ANHGY?
ANHGY faces various risks, including regulatory changes that may impact its operational framework and compliance requirements. Additionally, economic fluctuations could affect patient volumes and revenues, while intense competition from other healthcare providers poses a continuous threat. Currency risk related to international operations is also a consideration for investors.
What are the key factors to evaluate for ANHGY?
Mediclinic International plc (ANHGY) holds an AI score of 44/100 (low). Not financial advice.
How frequently does ANHGY data refresh on this page?
ANHGY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ANHGY's recent stock price performance?
Mediclinic International plc (ANHGY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive network of healthcare facilities across multiple regions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ANHGY overvalued or undervalued right now?
Valuing Mediclinic International plc (ANHGY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ANHGY?
Before investing in Mediclinic International plc (ANHGY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is sourced from company filings and market analysis as of March 2026.